Skip to content

Lung Cancer Research

Cancer ResearchLung cancer is the most common cancer in Yorkshire with around 5,800 people in the county being diagnosed each year. Although people who have never smoked can develop the disease, smoking is the main cause of lung cancer and is responsible for around 90% of cases. The most common symptoms of lung cancer are a long-standing cough that gets worse, persistent chest infections, coughing up blood, breathlessness, frequent tiredness or lack of energy, and a loss of appetite or unexplained weight loss.



Cancer ResearchPeripheral Blood detection of EGFR status in lung cancer patients

The more information doctors have about the exact characteristics of patient’s cancer, the more tailored the treatment can be. It is known that 10% of lung cancer sufferers have a faulty protein on the surface of their cancer cells because of a mutation in the EGFR gene. These patients will respond better to a specific type of treatment, known as tyrosine kinase inhibitors, than to conventional chemotherapy. Current methods of detecting these mutations rely on invasive biopsies, which may be too risky for some patients. Professor Lind’s team at the University of Hull are working to develop a device that can detect EGFR mutations from a non-invasive blood sample and identify those patients that can benefit from this tailored treatment.


  • Principle investigator: Professor Michael Lind
  • University of Hull
  • Award amount: £98,711
  • March 2016 – August 2017



Cancer ResearchRadiosensitizing agents for non-small cell lung cancer (NSCLC)

Radiotherapy is used to treat half of all patients with solid tumour cancers. However, the effectiveness of this treatment is limited by the damage it causes to healthy tissue and by the resistance of many tumours have to radiation. For example, the most common form of lung cancer, non-small cell lung cancer (NSCLC), is often radio-resistant.
In order to improve radiotherapy’s effectiveness it is sometimes used alongside chemotherapy, which can sensitise cancer cells to the treatment. Procedures currently used when combining these therapies may be further improved by use of a class of drugs called mitotic kinase inhibitors. These drugs affect the final stages of cell division, and may have the potential to enhance the effects of radiotherapy.


  • Principle investigator: Dr Helen Bryant
  • University of Sheffield
  • Award amount: £73,250
  • October 2015 – September 2018



Cancer ResearchCurative treatment modalities of early stage Non Small Cell Lung Cancer: Effect on Patient Reported Outcomes of Video Assisted Thoracoscopic (VATS) Resection and Stereotactic Ablative Body Radiotherapy (SABR)

There are two primary treatment options for early stage non-small cell lung cancer (NSCLC): surgery to remove the cancer or radiotherapy to kill the cancer cells. Professor Velikova’s team is examining how patients make the decision between these two treatment options. They will also help patients report any symptoms or problems arising after their treatment, and determine how they feel about the treatment decision process and the choices they made. This information can then be used to help other NSCLC patients make an informed decision about their treatment.


  • Principle investigator: Professor Galina Velikova
  • University of Leeds
  • Award amount: £200,083.47
  • January 2016 – December 2019



Cancer Types Icon
Information for researchers
Cancer Types Icon
Cancer Research Funded